Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,770 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572
Conditions
Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Interventions
Stereotactic boost, Conventional RT, Etoposide, Cisplatin
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
15
States / cities
Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more
Conditions
Stage III Non-small Cell Lung Cancer, Unresectable
Interventions
Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Anaheim, California • Duarte, California • Sacramento, California + 24 more
Conditions
MTAP-deleted Solid Tumors
Interventions
S095035, TNG462
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Conditions
Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD7789
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more
Conditions
Lung Cancer
Interventions
docetaxel, vinorelbine tartrate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
96
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
erlotinib hydrochloride, pemetrexed disodium
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
12
States / cities
Anchorage, Alaska • Bozeman, Montana • Kennewick, Washington + 7 more
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1081
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
Conditions
Solid Tumor, MET Alteration
Interventions
VERT-002
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Interventions
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 11 more
Conditions
Solid Tumor
Interventions
ASP4396
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more
Conditions
Non-Small Cell Lung Cancer
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ABR-217620, docetaxel
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Pembrolizumab, Trametinib
Biological · Drug
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Conditions
RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Interventions
TAS0953/HM06
Drug
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
9
States / cities
Orange, California • Stanford, California • Boston, Massachusetts + 5 more
Conditions
Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions
ZD1839 (Gefitinib)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
626
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more